We previously developed, and now approved, a humanized IgG4 PD1 mAb, HX008, which demonstrated strong antitumor activity across a variety of tumor types, a stable biochemical structure and a highly favorable pharmacokinetic property32–35. The gene discussed is PDCD1; the disease is neoplasm.